These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Economic evaluation for pharmaceuticals in Germany. Jönsson B Eur J Health Econ; 2007 Sep; 8 Suppl 1():S1-2. PubMed ID: 17638033 [No Abstract] [Full Text] [Related]
44. Evaluating rehabilitation using cost-consequences analysis: an example in Parkinson's disease. Gage H; Kaye J; Owen C; Trend P; Wade D Clin Rehabil; 2006 Mar; 20(3):232-8. PubMed ID: 16634342 [TBL] [Abstract][Full Text] [Related]
45. A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs? Clarke CE Mov Disord; 2004 May; 19(5):491-8. PubMed ID: 15133811 [TBL] [Abstract][Full Text] [Related]
46. Sensitivity analysis for handling uncertainty in an economic evaluation. Limwattananon S J Med Assoc Thai; 2014 May; 97 Suppl 5():S59-64. PubMed ID: 24964700 [TBL] [Abstract][Full Text] [Related]
47. A method for assessing the cost-effectiveness and the break-even point of clinical practice guidelines. Gandjour A; Lauterbach KW Int J Technol Assess Health Care; 2001; 17(4):503-16. PubMed ID: 11758295 [TBL] [Abstract][Full Text] [Related]
48. Burden of disease related to Parkinson's disease in Spain in the year 2000. Cubo E; Alvarez E; Morant C; de Pedro Cuesta J; Martínez Martín P; Génova R; Freire JM Mov Disord; 2005 Nov; 20(11):1481-7. PubMed ID: 16037922 [TBL] [Abstract][Full Text] [Related]
49. Economic evaluation and the postponement of health care costs. van Baal PH; Feenstra TL; Polder JJ; Hoogenveen RT; Brouwer WB Health Econ; 2011 Apr; 20(4):432-45. PubMed ID: 21210494 [TBL] [Abstract][Full Text] [Related]
50. Outcomes measurement: health state preferences and economic evaluation. Oldridge NB Assist Technol; 1996; 8(2):94-102. PubMed ID: 10163933 [TBL] [Abstract][Full Text] [Related]
51. Cost-effectiveness analysis as a measure of value. Garber AM Tecnologica; 1996 Jan; ():1, 3-6, 9-10. PubMed ID: 10170483 [No Abstract] [Full Text] [Related]
53. Value of research and value of development in early assessments of new medical technologies. Retèl VP; Grutters JP; van Harten WH; Joore MA Value Health; 2013; 16(5):720-8. PubMed ID: 23947964 [TBL] [Abstract][Full Text] [Related]
54. The management of patients with early Parkinson's disease. Rascol O; Brefel-Courbon C; Payoux P; Ferreira J Adv Neurol; 2003; 91():203-11. PubMed ID: 12442679 [No Abstract] [Full Text] [Related]
56. The economic value of medical technology. Gandjour A Health Aff (Millwood); 2002; 21(1):275-6. PubMed ID: 11900091 [No Abstract] [Full Text] [Related]
57. Bridging the credibility gap in cost effectiveness analysis. Siderowf A Mov Disord; 2014 Feb; 29(2):164-5. PubMed ID: 24338647 [No Abstract] [Full Text] [Related]
58. Cost-effectiveness analysis of organ transplantation. Scherstén T; Brynger H; Karlberg I; Jonsson E Int J Technol Assess Health Care; 1986; 2(3):545-52. PubMed ID: 10311837 [No Abstract] [Full Text] [Related]
59. Cost-effectiveness of sonography in India. Joshi MS Acad Radiol; 1996 Apr; 3 Suppl 1():S111-2. PubMed ID: 8796532 [No Abstract] [Full Text] [Related]
60. Reflections on NICE's Uptake of New Methods: Past, Present, and the 2020 Review. Boysen M; Watson I Pharmacoeconomics; 2020 Mar; 38(3):243-245. PubMed ID: 32016771 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]